Vaccination against group B streptococcus (Q36124960)

12 August 2017

1 reference

title

Vaccination against group B streptococcus (English)

1 reference

12 August 2017

Paul T Heath

1

0 references

author name string

Robert G Feldman

series ordinal

2

1 reference

12 August 2017

1 April 2005

1 reference

Expert Review of Vaccines

12 August 2017

1 reference

12 August 2017

4

1 reference

12 August 2017

2

1 reference

12 August 2017

207-218

1 reference

THE SEROLOGICAL DIFFERENTIATION OF PATHOGENIC AND NON-PATHOGENIC STRAINS OF HEMOLYTIC STREPTOCOCCI FROM PARTURIENT WOMEN.

12 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Suppurative meningitis due to streptococci of lancefield group B: A study of 33 infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Characterization of group B streptococci recovered from infants with invasive disease in England and Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Invasive disease due to group B Streptococcus in pregnant women and neonates from diverse population groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Group B streptococcal infection in older patients. Spectrum of disease and management strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Invasive group B streptococcal disease in adults. A population-based study in metropolitan Atlanta

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

High burden of invasive Streptococcus agalactiae disease in South African infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Group B streptococcal disease in UK and Irish infants younger than 90 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Estimated early-onset group B streptococcal neonatal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Systemic group B streptococcal disease in neonates and young infants in Norway 1985-94.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Meningitis in infancy in England and Wales: follow up at age 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Promising stratagems for reducing the burden of neonatal sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Risk factors and opportunities for prevention of early-onset neonatal sepsis: a multicenter case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Effects of intrapartum antimicrobial prophylaxis for prevention of group-B-streptococcal disease on the incidence and ecology of early-onset neonatal sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

A surface receptor specific for human IgA on group B streptococci possessing the Ibc protein antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Protein rib: a novel group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Identification of group B streptococcal Sip protein, which elicits cross-protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Preparation and properties of a protein (R antigen) occurring in streptococci of group A, type 28 and in certain streptococci of other serological groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

alpha-enolase, a novel strong plasmin(ogen) binding protein on the surface of pathogenic streptococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Identification of major outer surface proteins of Streptococcus agalactiae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Characterization of a novel leucine-rich repeat protein antigen from group B streptococci that elicits protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Biodegradable microspheres containing group B Streptococcus vaccine: immune response in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Group B streptococcal conjugate vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Conjugate vaccines against group B Streptococcus types IV and VII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Synthesis and preclinical evaluation of glycoconjugate vaccines against group B Streptococcus types VI and VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Immunization with C5a peptidase or peptidase-type III polysaccharide conjugate vaccines enhances clearance of group B Streptococci from lungs of infected mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Neonatal mouse immunity against group B streptococcal infection by maternal vaccination with recombinant anti-idiotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Immunochemical characterization of the "native" type III polysaccharide of group B Streptococcus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Intranasal immunization of mice with group B streptococcal protein rib and cholera toxin B subunit confers protection against lethal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Low prevalence of the immunoglobulin-A-binding beta antigen of the C protein among Streptococcus agalactiae isolates causing neonatal sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Novel protein vaccine candidates against Group B streptococcal infection identified using alkaline phosphatase fusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Genome sequence of Streptococcus agalactiae, a pathogen causing invasive neonatal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Nasal immunization with group B streptococci can induce high levels of specific IgA antibodies in cervicovaginal secretions of mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Immunization of pregnant women: reproductive, medical and societal risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Invasive Haemophilus influenzae type b disease in the Oxford region (1985-91)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Haemophilus influenzae type b disease in the Oxford region

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

FATAL INFECTIONS BY HqMOLYTIC STREPTOCOCCUS GROUP B

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

Preclinical evaluation of group B streptococcal polysaccharide conjugate vaccines prepared with a modified diphtheria toxin and a recombinant duck hepatitis B core antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.2.207

21 January 2018

Identifiers

DOI

10.1586/14760584.4.2.207

1 reference

12 August 2017

1 reference

PubMed ID

15889994